For the latest COVID-19 Travel restrictions and recommendations please click here

The poor success rate in developing a new drug from discovery to market is a major problem faced by the pharmaceutical industry today.
The goal of early ADME is to determine whether a candidate drug forms reactive metabolites as early as possible and mitigate attrition rates.
Reactive drug metabolites are known to be one of the factors behind unexpected drug-induced toxicity and therefore their identification early in the drug discovery process is of big importance.

Furthermore, cardiovascular toxicity is often to blame, accounting for approximately 27% of drug failures due to toxicity in the preclinical phase:
The overall attrition rate due to cardiovascular events in clinical development is 21%, indicating that several cardiovascular effects occur in Phase II and III clinical trials which are not detected in the preclinical studies or earlier clinical trials. Thus, the conference will feature a dedicated session on toxicity and highlight emerging technology to aid better prediction.


ADME parameters obtained from in vitro and in vivo models, which aid in the prediction of drug behaviors in patients, are important for the decision to advance, hold or terminate a drug candidate. However, incomplete ADME studies or misinterpretation of ADME data may cause failures in drug development. ADME studies are conducted with in vitro, in vivo or in silico models.

In vitro models generate many ADME parameters, including apparent permeability, metabolic stability, protein binding, blood-to-plasma partitioning, drug–drug interaction potentials (e.g., inhibition and induction of cytochrome P450 (CYP) and transporters), cell proliferation and cytotoxicity, and hERG inhibition. In vivo models of animals and healthy human subjects provide information such as drug oral bioavailability, exposures, distribution, clearance, and duration of exposure for a drug and its metabolites.

Finally, in silico models predict drug behaviors based on physicochemical properties of drug candidates in combination with crystal structures of a protein (an enzyme or a transporter) and database of ADME properties generated in laboratories. With the numerous models available, proper experimental model selection is essential for ADME property optimization.



The conference will draw focus on:
• Progresses in AMDET-enabling technologies
• Human ADME studies and challenges with standardisation.
• Emerging assays to monitor cardiotoxicity
• Lead optimisation of PK/PD modelling
• In Silico modelling techniques
• Drug-Drug interaction 
 • Learn new stratgeies of optimising in vitro/ in vivo extrapolation
• Translation issues of animal-derived metabolic results to predict human drug metabolism
• Emerging assays to monitor cardio toxicity and hepatotoxicity
• Regulatory guidelines on safety and toxicity risk assessments


Admescope Ltd; Astra Zeneca; AstraZeneca; Biolab Sanus Farmaceutica Ltda; Cancer Research Technology; Cancer Research Technology Ltd; Corning Life Sciences; CXR Biosciences; Debiopharm; Eisai Pharmaceuticals; EligoChem Ltd; Galapagos NV; Genentech, Inc.; GlaxoSmithKline; GSK; Imperial College London; Ipsen Pharma; Janssen Strategic Marketing; Johnson & Johnson; King's College London; Lexicon Pharmaceuticals Inc; Medicyte GmbH; Northeastern University; Novartis AG; Novartis Pharma; Novo Nordisk A/S; Peakdale Molecular Ltd; Proximagen; Roche Pharmaceuticals; Sanofi-Aventis Deutschland GmbH; Shire plc; Sovicell; Takeda Pharmaceuticals Europe; The Edge; The Institute of Cancer Research; The Research Network Ltd; TranScrip Partners; UCB; University Of Sussex; Vertex Pharmaceuticals; Xenotech;

Conference programme

8:30 Registration & Coffee

9:00 Chair's Opening Remarks

Araz Raoof

Araz Raoof, Head Scientific Affairs & Analysis, Janssen Pharmaceutica

9:10 OPENING ADDRESS: How is ADMET Tackling Key Challenges of Drug Development?

Araz Raoof

Araz Raoof, Head Scientific Affairs & Analysis, Janssen Pharmaceutica


·          The role of ADME in drug discovery and its impact on clinical attrition rate
·          Bridging the translational gap from bench to bed
·          Future outlook of ADME in drug development

9:50 In Silico DMPK: A Bridging Position

Fabio Broccatelli

Fabio Broccatelli, Scientist, Genentech, Inc.



·          Maximizing the value of experimental data through modelling and data mining
·          Real life examples of how models can influence project teams
·          In Silico DMPK, an environment for pre-competitive collaboration

10:30 Morning Coffee

11:00 SPONSORED SESSION: How we set about revolutionizing in-vitro membrane drug transporter assays

Paul Brooks

Paul Brooks, Head of Discovery Research Services, Sigma Aldrich



The drug discovery process is both a high cost and high risk endeavour. It has been estimated that bringing a drug candidate to market can cost in the range of $1–2 billion dollars and typically takes 12 years to complete. It is therefore no surprise that withdrawal in the later stages of this process is devastatingly expensive to the pharmaceutical industry. An obvious improvement to these high costs and long timelines is to find ways to eliminate non-viable drug candidates from therapeutic programs much earlier in the process. This has made the ADME and toxicology stages of drug discovery a focal point for improvements by the pharmaceutical industry. Advances in ADME and toxicology studies have the potential to increase the probability of success, decrease overall costs and reduce the time to market.

In this seminar we highlight one such advance in the use of genetically modified cell lines that improve upon, and simplify, in-vitro membrane drug transporter research. These cell lines hold the potential to help clarify complex drug-transporter interactions without some of the limitations of current chemical or genetic knockdown approaches.

· Learn about the latest assays for drug transporter investigations.
· Discover how these assays relate to the FDA and EMA Guidances for Drug Interaction Studies.

11:40 Complementary use of high-throughput ADMET screening and In Silico modelling systems to strengthen non-animal alternatives

Mark Wenlock

Mark Wenlock, Research Scientist, AstraZeneca


  •  Supervised integration of experimental data to maximise the predictive quality of In Silico modeling
  •  Optimising predictive parameters to make the best informed decisions
  •  Mitigating errors in early human dose predictions and setting the criteria for ADME end points
  • 12:20 Networking Lunch

    13:30 KEYNOTE ADDRESS: Opportunities for modelling of kidney disease and general toxicology studies.

    Jamie Davies

    Jamie Davies, Professor of Experimental Anatomy, University Of Edinburgh


  • The human relevance, sensitivity and specificity of current experimental models
  • Use of emerging technologies in 3D cell culture to predict hepatotoxicity
  • Current challenges in determining underlying mechanisms of toxicity
  • Enabling complete metabolism studies, confirmation of structure and quantitative measures of toxicity.
  • CYP activities and sensitivities to multiple model hepatotoxins
  • 14:10 Transational PK/PD modeling for efficacy and safety

    Thierry Lave

    Thierry Lave, Head DMPK and TOX Project Leaders and Modeling & Simulation, F. Hoffmann-La Roche


    • Value of integrating translational PKPD in early development
    • Understand the requirements for translational PKPD
    • Illustrate use of exposure-response modelling to:
      • optimize FIH study designs
      • aid dose selection for proof of concept studies
      • translate from preclinical to clinical 

    14:50 Dealing with the challenges of making an accurate human dose prediction

    Peter Littlewood

    Peter Littlewood, Director DMPK, Vertex Pharmaceuticals


    ·          Accurately profiling metabolic pathways and unexpected metabolites
    ·          PK/PD models that support in vitro to in vivo extrapolation
    ·          Challenges with biological barriers
    ·          Impact of genetic variations on predictive PK/PD modelling for dose regimes


    15:30 Afternoon Tea

    16:10 Exploratory ADME in preclinical and clinical studies to guide and accelerate clinical development

    Mario Monshouwer

    Mario Monshouwer, Senior Director Drug Metabolism Pharmacokinetics & Bioanalysis, Johnson & Johnson


    ·          The value of mechanism based drug disposition to drive decision making
    ·          Role of humanized mouse models to obtain mechanistic insights on pharmacokinetics
    ·          Including microtracers and endogenous markers for CYP3A4/5 during phase 1 studies.

    16:50 Application of PK/PD Modelling in ADMET

    Laurent Salphati

    Laurent Salphati, Senior Scientist, Genentech


    ·          Optimising the translational use of preclinical PK/PD modelling in drug development
    ·          Predictive quality of PK/PD models in oncology
    ·          Case study: tumour growth inhibition and setting targets for clinical efficacy

    17:30 Panel Discussion


    ·          How useful are the cut-off values set out by FDA/EMA guidelines in determining CYP inhibition?
    ·          The challenge to the drug developer is deciding how to invest resources appropriately to address the MIST requirements at a stage of development when the risk-benefit ratio of a drug is still largely unknown.
    ·          What ADMET studies should be performed for pre-clinical studies?
    Araz Raoof

    Araz Raoof, Head Scientific Affairs & Analysis, Janssen Pharmaceutica

    Laurent Salphati

    Laurent Salphati, Senior Scientist, Genentech

    Jamie Davies

    Jamie Davies, Professor of Experimental Anatomy, University Of Edinburgh

    18:10 Chair’s Closing Remarks and Close of Day One

    Araz Raoof

    Araz Raoof, Head Scientific Affairs & Analysis, Janssen Pharmaceutica

    8:30 Registration & Coffee

    9:00 Chair's Opening Remarks

    Ian D. Wilson

    Ian D. Wilson, Professor of Drug Metabolism and Molecular Toxicology, Imperial College London

    9:10 OPENING ADDRESS: Future perspectives of ADMET evaluations and the current paradigm shifts in toxicology

    Ian D. Wilson

    Ian D. Wilson, Professor of Drug Metabolism and Molecular Toxicology, Imperial College London

  • State-of-the-art analytical methods for screening drug metabolism
  • Evaluating biotransformation and reactive metabolite production
  • Advances in in vivo models to accurately predict human metabolism and toxicity

  • 9:50 Assessing transporter-mediated drug-drug interactions

    Guy Webber

    Guy Webber, Scientific Manager for In Vitro and Discovery Services ,

  • Review of current in vitro models available and practical considerations of transporter testing
  • Regulatory DDI Guidance(s) for drug transporters - an overview review of current FDA, EMA and JMHLW (Japan) guidance for industry

    10:30 Morning Coffee

    11:00 Metabolic Drug-Drug Interactions due to CYP Enzyme Inactivation (Time-Dependent Inhibition)

    Stephen Fowler

    Stephen Fowler, ADME Group Leader, In Vitro ADME, F. Hoffmann-La Roche


  • Effects of enzyme inactivation and how to screen for this
  • Chemistries often associated with time-dependent CYP inhibition
  • Assessment of TDI risk
  • 11:40 Toxicology pathways – Evidence-based mechanistic modelling

    Nick Plant

    Nick Plant, Reader in Molecular Toxicology, University Of Surrey


  • What are we lacking in evidence-based toxicology?
  • Identifying interactions and predicting emergent phenotypes
  • Using mechanistic modelling to drive early drug discovery
  • 12:20 Networking Lunch

    13:30 Predicting human drug-Induced hepatotoxicity

    Gerry Kenna

    Gerry Kenna, Director, FRAME


      • Idiosyncratic vs. dose dependent drug hepatotoxicity
      • Drug-related initiating mechanisms and patient-related susceptibility factors
      • Value and limitations of conventional toxicity studies in animals
      • Opportunities provided by transgenic and chimeric humanized animal models
      • Use of in vitro models to de-risk drug related liabilities
      • Challenge of tackling inter-species and inter-individual variability

    14:10 New strategies to reduce drug induced cardiovascular toxicity

    Peter K Hoffmann

    Peter K Hoffmann, Global Preclinical Expert for Cardiovascular Safety, Novartis Institutes for BioMedical Reseach


  • Concordance of preclinical and clinical QT data
  • Comprehensive in vitro pro-arrhythmia assay (CiPA)
  • Translatability of preclinical contractility data
  • Expanding in vitro models for earlier drug safety assessment
  • Human stem cell derived cardiomyocytes
  • 14:50 Afternoon Tea

    15:20 In vitro models and technologies for detecting Cardiotoxicity

    Peter  Clements

    Peter Clements, Director of Pathology, GSK


    ·          Integrated use of in vitro models to detect cardiotoxicity in a safety screening strategy
    ·          Progress of hERG/ion channel inhibition as a pre-clinical tool
    ·          Use of surrogate biomarkers for cardiac safety predictions
    ·          Can in vitro data predict pathology in toxicology or clinical studies?
    ·          State-of-the art Human cellular models to reduce reliance of animal-based prediction

    16:00 Which in vitro models, technologies and strategies to detect Hepatotoxicity and Cardiotoxicity at early stages of drug development?

    Frank Atienzar

    Frank Atienzar, Associate Director In Silico in Vitro Toxicology, UCB BioPharma SPRL


  • Performance of different in vitro models to detect human hepatotoxic drugs
  • Comparison of metabolic patterns in different in vitro models  
  • CIPA initiative (proarrhythmia): non-clinical safety testing paradigm shift and impact on strategy
  • Label free technologies applied to drug discovery  
  • 17:20 Chair’s Closing Remarks and Close of Day Two

    Ian D. Wilson

    Ian D. Wilson, Professor of Drug Metabolism and Molecular Toxicology, Imperial College London



    Paul Brooks

    Paul Brooks

    Head of Discovery Research Services, Sigma Aldrich

    Araz Raoof

    Head Scientific Affairs & Analysis, Janssen Pharmaceutica
    Araz Raoof

    Fabio Broccatelli

    Scientist, Genentech, Inc.
    Fabio Broccatelli

    Frank Atienzar

    Associate Director In Silico in Vitro Toxicology, UCB BioPharma SPRL
    Frank Atienzar

    Gerry Kenna

    Director, FRAME
    Gerry Kenna

    Guy Webber

    Scientific Manager for In Vitro and Discovery Services ,
    Guy Webber

    Ian D. Wilson

    Professor of Drug Metabolism and Molecular Toxicology, Imperial College London
    Ian D. Wilson

    Jamie Davies

    Professor of Experimental Anatomy, University Of Edinburgh
    Jamie Davies

    Laurent Salphati

    Senior Scientist, Genentech
    Laurent Salphati

    Mario Monshouwer

    Senior Director Drug Metabolism Pharmacokinetics & Bioanalysis, Johnson & Johnson
    Mario Monshouwer

    Mark Wenlock

    Research Scientist, AstraZeneca
    Mark Wenlock

    Nick Plant

    Reader in Molecular Toxicology, University Of Surrey
    Nick Plant

    Paul Brooks

    Head of Discovery Research Services, Sigma Aldrich
    Paul Brooks

    Peter Clements

    Director of Pathology, GSK
    Peter  Clements

    Peter K Hoffmann

    Global Preclinical Expert for Cardiovascular Safety, Novartis Institutes for BioMedical Reseach
    Peter K Hoffmann

    Peter Littlewood

    Director DMPK, Vertex Pharmaceuticals
    Peter Littlewood

    Stephen Fowler

    ADME Group Leader, In Vitro ADME, F. Hoffmann-La Roche
    Stephen Fowler

    Thierry Lave

    Head DMPK and TOX Project Leaders and Modeling & Simulation, F. Hoffmann-La Roche
    Thierry Lave

    Sponsors and Exhibitors


    Is your name on the list for ADMET 2015?


    ADMET Speaker Interview with FRAME


    Sponsors and Exhibitors


    Sponsors and Exhibitors

    Corning is a global manufacturer of tools and equipment for cell culture, genomics, drug discovery, and microbiology. Our Corning®, Falcon®, Axygen®, and Gosselin™ brands include: vessels and differentiated surfaces for cell culture and scale-up, media, liquid handling products, ADME/Tox products and services, and microbiology consumables.


    Sponsors and Exhibitors

    Sigma-Aldrich, a leader in the manufacture of Reference Materials and CRMs, recently launched an extensive range of microorganism Certified Reference Materials in an easy to use disc format. A new partnership with Public Health England provides key R&D into new CRMs. Microbiology media, PCR and genomics reagents complete the portfolio for Microbiology.

    Media Partners

    Bioportfolio Limited


    BioPortfolio.com is a leading news, information and knowledge resource covering the global life science industries impacted by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to source core information on specific bio-related topics, to collate relevant data associated with each topic and to point the user to relevant knowledge resources



    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com



    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.



    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.



    LabRoots is a free, social networking site that enables scientists, engineers, and other technical professionals to connect, collaborate with, and learn from each other. LabRoots fosters world-wide scientific communication and incorporates the newest social networking technologies. LabRoots allows scientists to connect with each other as they describe their research interests on a myriad of unique features and tools, discovering meaningful collaborations across geographic boundaries and fields of expertise.

    Technology Networks


    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com



    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!



    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!

    International Journal of Biotechnology


    IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.

    International Pharmaceutical Industry


    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.

    Medical News Today


    Medical News Today is the largest independent medical and health news site on the web - with over 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact peter@medicalnewstoday.com or visit www.medicalnewstoday.com.



    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/



    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.

    Select Science


    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.



    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.

    http://www.fiercebiotech.com" target="_blank"> sponsor image


    http://www.fiercebiotech.com" target="_blank" class="link" align="right"> http://www.fiercebiotech.com

    FierceBiotech is the biotech industry's daily monitor. Biotech executives rely on FierceBiotech to stay up to speed on biotech corporations, FDA approvals & regulations, industry mergers & acquisitions, clinical trials, and more. Beyond the news of the day, our editors produce in-depth features on industry leaders and up-and-comers, the regulatory environment, and market trends. In addition to our comprehensive website and free email newsletter, you have the opportunity to attend our webinars, peruse our whitepaper library and benefit from our eBooks. Advance your career through our exclusive networking parties and life sciences job board.



    www.PharmCast.com is the world leading website designed specifically for pharmaceutical, clinical and biotechnology professionals. www.PharmCast.com brings up-to-date information on pharmaceutical patents, FDA, news, jobs and Buyer's Guide to our visitors. It was created and is maintained by pharmaceutical and biotechnology professionals. Visit www.PharmCast.com and discover for yourself why it is so popular among professionals.



    PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.

    Contract Biotechnology


    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.

    Pharmaceutical Technology


    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.



    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.



    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.

    Drug Development Technology


    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.

    International Journal of Bioinformatics Research and Applications


    Bioinformatics is an interdisciplinary research field that combines biology, computer science, mathematics and statistics into a broad-based field that will have profound impacts on all fields of biology. The emphasis of IJBRA is on basic bioinformatics research methods, tool development, performance evaluation and their applications in biology. IJBRA addresses the most innovative developments, research issues and solutions in bioinformatics and computational biology and their applications.

    International Journal of Medical Engineering and Informatics


    IJMEI promotes an understanding of the structural/functional aspects of disease mechanisms and the application of technology towards the treatment/management of such diseases. It seeks to promote interdisciplinary collaboration between those interested in the theoretical and clinical aspects of medicine and to foster the application of computers and mathematics to problems arising from medical sciences. IJMEI includes authoritative review papers, the reporting of original research, and evaluation reports of new/existing techniques and devices. Each issue also contains a comprehensive information service.



    Bentham Science


    Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks provide professionals, academicians, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham is offering attendees of this conference discounts on its publication. For more information click here



    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.

    Cutting Edge


    Cutting Edge Information provides customized research and benchmarking reports to pharmaceutical, biotechnology and other life science companies. We provide off-the-shelf and customized research for key areas including medical affairs, clinical development, market access, regulatory affairs, marketing management, sales and HCP fair market value.

    Drug Discovery Today


    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.

    International Journal of Computational Biology and Drug Design


    IJCBDD, an International Society of Intelligent Biological Medicine official journal, bridges the gap between two very important, complementary disciplines, computational biology and drug design. Through advances in high-throughput genome sequencing and digital imaging technologies, biocomputing, drug design and medical research have unfolded new, predictive sciences such as genomics, proteomics, lipidomics, metabolomics, cytomics and pharmaconomics. These promote new computational, statistical and biomedical approaches to drug design/development, besides unleashing the potential of significantly more accurate, effective personalised diagnosis, therapeutics and patient care.

    Lab Bulletin


    Lab Bulletin is a free online resource for scientists and laboratory professionals where you can catch up on the latest news for laboratory products and services. You will find an extensive directory of laboratory suppliers and manufacturers enabling you to contact companies quickly and easily to request further information. Lab Bulletin also publishes four free monthly E-Newsletters keeping you up-to-date with all of the latest laboratory products and industry news directly to your inbox. We have dedicated E-Newsletters for Chromatography and Spectroscopy, Microscopy and Image Analysis, weekly Industry News updates and our monthly Lab Bulletin E-Newsletter sent out to over 29,000 readers worldwide. To request your free copy click here



    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.

    Marriott Regents Park

    128 King Henry's Road
    London NW3 3ST
    United Kingdom

    Marriott Regents Park

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.



    speaker image






    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title


    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event


    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71

    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out